CREST Syndrome (Limited Systemic Sclerosis)
CREST syndrome is a limited form of systemic sclerosis (SSc) and belongs to the group of autoimmune connective-tissue diseases. The condition is characterized by fibrosis of the skin and internal organs together with vascular and immunological abnormalities. CREST is an acronym describing five central clinical features: Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly and Telangiectasia. Unlike diffuse systemic sclerosis, the skin changes in CREST syndrome are mainly limited to the face and distal extremities, and disease progression is generally slower.
Calcinosis involves deposition of calcium salts in the skin and subcutaneous tissue, often producing painful, hard nodules. These may lead to ulceration, infection, and reduced function in affected areas².Raynaud phenomenon is often the first clinical sign and is characterized by episodic vasospasm in the fingers and toes, typically triggered by cold exposure or emotional stress. It causes characteristic color changes—white from ischemia, blue from cyanosis, and red from reactive hyperemia.Esophageal dysmotility causes reduced motility in the lower esophagus and impaired function of the lower esophageal sphincter, which can result in reflux, dysphagia, and an increased risk of aspiration.Sclerodactyly describes sclerotic skin changes that make the fingers thin, stiff, shiny, and less mobile. This results from fibrosis of both the dermis and subcutaneous tissue³.Telangiectasia refers to dilated superficial capillaries, most often affecting the face, hands, and mucous membranes, and reflects the microvascular abnormalities associated with systemic sclerosis⁴.
Epidemiology
Systemic sclerosis is a relatively uncommon disease, and prevalence varies by region. Reported prevalence in North America ranges from approximately 13.5 to 44.3 per 100,000 people, while European estimates are somewhat lower, ranging from about 7.2 to 33.9 per 100,000⁵. Changes in reported prevalence over time likely reflect improved diagnosis, better classification systems, and increased survival.
CREST syndrome accounts for approximately 22–25% of systemic sclerosis cases in some serological studies⁶. The condition predominantly affects women, with reported female-to-male ratios ranging from 3.8:1 to 15:1. Average age at diagnosis varies geographically, with estimates ranging from 33.5 to 59.8 years in Europe and 46.1 to 49.1 years in North America⁵. Epidemiological research specifically separating CREST syndrome from systemic sclerosis remains limited, but it is regarded as an important clinical subgroup because of its characteristic presentation and generally more favorable prognosis than diffuse systemic sclerosis.
Pathophysiology
CREST syndrome falls within the systemic sclerosis disease spectrum, whose pathogenesis is characterized by a classic triad of vascular injury, immune activation, and tissue fibrosis⁷.
1. Endothelial Dysfunction and Apoptosis
An early event in disease development is thought to be injury to the vascular endothelium, followed by apoptosis of endothelial cells. This initiates a cascade involving activation of coagulation pathways, recruitment of immune cells, and chronic inflammation.
2. Immune Activation
Both the innate and adaptive immune systems become activated. M1 macrophages, which are pro-inflammatory, and M2 macrophages, which are pro-fibrotic, are important contributors. They promote production of inflammatory cytokines and growth factors that stimulate fibroblasts to produce connective tissue. Autoantibodies such as anticentromere antibodies, anti-topoisomerase I (Scl-70), and anti-RNA polymerase III are commonly associated with systemic sclerosis and support diagnostic classification.
3. Fibrosis and Excess Extracellular Matrix Production
Persistent activation of myofibroblasts derived from several mesenchymal cell populations, including fibroblasts, pericytes, and endothelial cells, results in excessive production of collagen, fibronectin, and tenascin C. These components accumulate in tissue and increase stiffness while reducing elasticity and organ function. Myofibroblasts also undergo metabolic and epigenetic changes, including increased glycolysis and altered NAD⁺ balance. Their resistance to apoptosis may further sustain disease progression through a self-reinforcing fibrotic response⁷.
Features of Limited Cutaneous Systemic Sclerosis (CREST)
In limited cutaneous systemic sclerosis, vascular endothelial injury is thought to promote infiltration of mononuclear cells. This may alter Th1/Th2 immune signaling and generate cytokine patterns that stimulate fibroblasts to increase collagen production⁸. These mechanisms may help explain the localized fibrosis and vasculopathy that dominate the clinical picture of CREST syndrome.
Diagnosis
Systemic sclerosis, including CREST syndrome, is diagnosed using a combination of clinical findings, autoantibody testing, and relevant investigations. No single test can definitively confirm or exclude the diagnosis. According to the 2013 classification criteria, the following features are considered⁹:
Major criterion:
Skin thickening of both hands extending proximally beyond the metacarpophalangeal (MCP) joints is sufficient by itself for classification as systemic sclerosis.
Additional criteria:
Finger skin changes: puffy fingers or sclerodactyly distal to the MCP joints.
Fingertip lesions: digital ulcers or fingertip pitting scars.
Telangiectasia
Abnormal nailfold capillaries: assessed by nailfold capillaroscopy.
Pulmonary manifestations: pulmonary arterial hypertension and/or interstitial lung disease.
Raynaud phenomenon
Systemic-sclerosis-specific autoantibodies:
Anticentromere antibodies
Anti-topoisomerase I (anti-Scl-70)
Anti-RNA polymerase III
The more additional criteria that are present, the greater the likelihood that classification criteria are fulfilled. These criteria can facilitate earlier recognition and multidisciplinary follow-up.
Etiology
Although the exact cause of CREST syndrome remains unknown, the disease is thought to result from a complex interaction between genetic susceptibility, immune dysregulation, and environmental influences. As in many autoimmune disorders, the immune system inappropriately targets the body's own tissues, particularly blood vessels and connective tissue.
Genetic Factors
Systemic sclerosis occurs more frequently in some families, and variants in the human leukocyte antigen (HLA) gene complex have been associated with altered disease susceptibility. Certain HLA variants may influence how the immune system recognizes self-antigens and contribute to autoimmune activation.
Immune Dysregulation
Disrupted immune regulation promotes overproduction of cytokines and autoantibodies that stimulate fibroblasts to produce excessive collagen and extracellular matrix. This contributes to progressive fibrosis in the skin and internal organs.
Environmental Triggers
Potential environmental factors include exposure to silica, organic solvents, and certain medications. Infections and other non-genetic influences have also been proposed as possible triggers or modifiers of disease development, although causal relationships remain incompletely understood.
Calcinosis – A Central Component of CREST Syndrome
Approximately 40% of patients with limited cutaneous systemic sclerosis (lcSSc) develop soft-tissue calcium deposits known as calcinosis cutis¹⁰. These consist of insoluble calcium salts in the skin and subcutaneous tissue despite normal blood calcium and phosphate levels. This is referred to as dystrophic calcification, which occurs without a systemic disturbance of mineral metabolism.
Proposed Mechanisms Behind Calcinosis:
Chronic hypoxia: Hypoxia in peripheral tissue, particularly in the fingers and toes, is considered a possible contributing factor. It may promote tissue injury, inflammation, and local calcium deposition. Clinical signs of impaired peripheral perfusion in CREST can include:
Digital ulcers
Loss of fingertip tissue
Capillary 'drop-out' on nailfold capillaroscopy
Repetitive trauma: Microtrauma and repeated loading of small joints and skin areas, such as the fingertips and extensor surfaces of the limbs, may promote calcification in already vulnerable tissue. This is supported by the frequent location of calcinosis in these areas.
Local Tissue Injury and Inflammation: Persistent local tissue damage and inflammation may create an environment that promotes calcium-crystal deposition. These deposits can cause pain, restricted mobility, infection risk, and occasionally require surgical management.
Calcific deposits vary in size and consistency and are most often found in the fingers, elbows, knees, and gluteal region. Clinically, they may appear as firm, whitish nodules beneath the skin and can occasionally perforate through the skin with discharge of chalk-like material.
Raynaud Phenomenon
Raynaud phenomenon occurs in up to 90% of patients with systemic sclerosis and is often the first clinical sign of the disease¹¹. It is a vasospastic disorder causing sudden, recurrent episodes of reduced blood flow to the fingers and toes, usually triggered by cold exposure or emotional stress. Clinically, it is characterized by a triphasic color change—white from ischemia, blue from cyanosis, and red from reactive hyperemia.
In systemic sclerosis, Raynaud phenomenon results from several interacting mechanisms. Capillary endothelial cells may be damaged through immune-mediated processes, producing an imbalance between vasoconstrictors and vasodilators, for example increased endothelin-1 and reduced nitric oxide production¹². Microangiopathy also produces structural vascular changes, while intravascular processes may contribute to vessel occlusion. Together these mechanisms impair digital perfusion and produce the characteristic manifestations of Raynaud phenomenon.
Esophageal Dysmotility
Gastrointestinal manifestations are very common in systemic sclerosis, and more than 90% of patients experience some form of gastrointestinal dysfunction. Esophageal dysmotility is particularly common and may present with reflux, heartburn, and difficulty swallowing. In addition to causing substantial symptoms, esophageal dysfunction may contribute to aspiration and is associated with pulmonary complications that can adversely affect prognosis¹³.
The pathophysiology of esophageal involvement in systemic sclerosis is not fully understood. Vascular injury and fibrosis may contribute, although some biopsy studies have demonstrated muscular atrophy without prominent inflammation or fibrosis. Atrophy of esophageal smooth muscle, potentially related to microvascular and autonomic dysfunction, may be central to the development of motility impairment.
Over time, esophageal involvement can lead to complications such as Barrett's esophagus, strictures, and esophageal malignancy, all of which require appropriate medical surveillance.
Sclerodactyly
Sclerodactyly refers to thickening and tightening of the skin over the fingers and is a characteristic component of CREST syndrome. The pathological process begins with perivascular inflammation in the dermis, followed by increased production and deposition of type I and III collagen, mucopolysaccharides, and glycoproteins¹⁴. This produces an initial edematous phase that can progress to marked fibrosis.
A parallel process occurs in the small digital arteries, where the intima thickens and the adventitia may become infiltrated by inflammatory cells before fibrosis develops¹⁵. These vascular changes narrow the lumen and can promote thrombosis and tissue ischemia. Over time, the skin may become thin and atrophic even after the fibrotic phase has stabilized.
Telangiectasia
Telangiectasias are dilated small blood vessels near the skin surface and are a common visible feature of CREST syndrome. They typically occur on the hands, face, and mucous membranes, although the reason for this distribution is not fully understood¹⁶. Although both Raynaud phenomenon and telangiectasia occur in CREST syndrome, telangiectasia is not a feature of primary Raynaud phenomenon, suggesting that vasospasm alone does not explain its development.
Proposed mechanisms such as venous hypertension do not adequately explain their distribution, because increased venous pressure is rarely present in these areas. Telangiectasia therefore reflects the underlying microvascular pathology characteristic of systemic sclerosis, although aspects of its pathogenesis remain uncertain.
Medical Management
Because systemic sclerosis, including CREST syndrome, affects both physical health and psychosocial well-being, management requires a comprehensive approach. Organ involvement should be assessed carefully, patients should receive clear education about the disease course, and both patients and families may require ongoing support. Treatment is individualized according to disease severity and organ involvement, and follow-up by a rheumatologist experienced in systemic connective-tissue disease is recommended¹⁷.
Organ-directed treatment can influence disease complications, progression, and quality of life. Targeted interventions should therefore be selected according to specific manifestations and complications¹⁸.
Organ-Directed Treatment in CREST Syndrome
Manifestation | Recommended Treatment |
Arthralgia (Joint Pain) | NSAIDs may be used when appropriate for pain; disease-modifying treatment such as methotrexate may be considered when inflammatory musculoskeletal involvement is present under rheumatology supervision. |
Advanced Pulmonary Disease | Lung transplantation may be considered in selected patients with severe, irreversible end-stage pulmonary disease. |
Gastroesophageal Reflux | Proton-pump inhibitors (PPIs) for acid suppression; prokinetic therapy such as metoclopramide may be considered for selected patients with impaired motility. |
Intestinal Dysmotility | Antibiotics may be used for small-intestinal bacterial overgrowth and malabsorption; prokinetic agents may be considered to improve motility. |
Pulmonary Hypertension | Pulmonary arterial hypertension requires specialist-directed therapy. Depending on the hemodynamic phenotype and severity, treatment may include endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin-pathway therapies, and other targeted agents. |
Inflammatory Lung Disease | Immunomodulatory or immunosuppressive treatment may be used for active systemic-sclerosis-associated interstitial lung disease according to specialist assessment and current treatment guidelines. |
Inflammatory Myositis | Treatment depends on the inflammatory myopathy phenotype and may include corticosteroids and/or steroid-sparing immunomodulatory therapy under specialist supervision. |
Raynaud Phenomenon | Calcium-channel blockers, phosphodiesterase-5 inhibitors, topical nitrates, prostacyclin-pathway therapies, and other vasoactive treatments may be used according to symptom severity; patients should also minimize cold exposure. |
Scleroderma Renal Crisis | Urgent blood-pressure control with an ACE inhibitor is central to management; dialysis may be required when severe renal failure develops. |
Specific Treatment Strategies in CREST Syndrome
Management of Raynaud Phenomenon
In a substantial proportion of patients with systemic sclerosis, Raynaud phenomenon becomes severe and may lead to ischemic complications and digital ulcers¹⁹. Management of Raynaud phenomenon and digital ulcers is closely linked because optimal control of vasospasm and vascular dysfunction is important for ulcer prevention. A comprehensive approach combines lifestyle measures with pharmacological treatment.
Measures include:
Lifestyle modification: Protection from cold, smoking cessation, stress reduction, and patient education are important first-line preventive measures.
Vasoactive medication: Calcium-channel blockers such as nifedipine, phosphodiesterase-5 inhibitors, prostacyclin analogues, and other vascular therapies may be used to improve digital blood flow depending on clinical severity.
Treatment of acute digital ulcers: Infection, necrosis, and severe ischemia may require antibiotics, analgesia, wound care, and urgent specialist assessment. Severe ischemic digital ulcers can constitute a medical emergency²⁰.
Management of Calcinosis Cutis
Calcinosis cutis is a difficult complication of limited cutaneous systemic sclerosis and may cause painful or ulcerated nodules. Pharmacological treatment has generally shown limited and inconsistent benefit.
Management options include:
Medications that have been investigated: Bisphosphonates, intralesional corticosteroids, aluminum hydroxide, warfarin, and calcium-channel blockers such as diltiazem have been tried, but evidence for consistent benefit is limited.
Surgical removal: Local excision may be considered for painful, recurrently infected, or ulcerated lesions. Recurrence is common²¹.
Management of Esophageal Dysmotility and Gastrointestinal Involvement
More than 90% of patients with systemic sclerosis develop gastrointestinal involvement, with esophageal dysmotility among the most common manifestations²². This may cause severe reflux, dysphagia, and complications such as Barrett's esophagus.
Management Strategies by Gastrointestinal Region:
Gastrointestinal Region | Management |
Oral Cavity | Orofacial exercises, saliva substitutes, and medications that stimulate salivary secretion may be considered when xerostomia is present. |
Esophagus | Lifestyle measures may include elevating the head during sleep, avoiding individual reflux triggers, and eating smaller, more frequent meals. Proton-pump inhibitors are commonly used for reflux. Endoscopic dilation may be required for significant strictures, while dysplastic Barrett's epithelium is managed according to gastroenterology guidelines. |
Stomach | Dietary modification, including smaller meals and individualized adjustment of fat and fiber intake, may be useful in gastroparesis; nutritional supplementation may be required when intake is inadequate. |
Small Intestine | Antibiotic treatment may be used for small-intestinal bacterial overgrowth (SIBO), with drug choice guided by clinical assessment and local practice. |
Colon and Anorectum | Laxatives, stool softeners, dietary measures, and other bowel-regulation strategies may be used for constipation according to individual symptoms. |
Management of Skin Manifestations
Limited cutaneous systemic sclerosis can cause substantial cosmetic and functional problems. Conventional medication has limited ability to reverse established skin fibrosis. Autologous fat grafting has been investigated as a newer reconstructive approach.
Interventions include:
Autologous Fat Transfer (AFT): A surgical technique using autologous adipose tissue containing adipose-derived stromal and stem cells. Studies have reported improvements in hand and oral function, Raynaud symptoms, and digital-ulcer burden in selected patients²³.
Proposed mechanism: Adipose-derived stromal cells may have regenerative, angiogenic, and anti-inflammatory properties.
Safety: AFT is generally regarded as a procedure with a relatively low complication rate in appropriately selected patients, but further research is needed to standardize techniques and indications.
Physiotherapy Management in CREST Syndrome
Physiotherapists can play an important role within the multidisciplinary rheumatology team and require appropriate knowledge of the complex functional problems associated with systemic sclerosis, including CREST syndrome²⁴.
Clinical Assessment and Functional Evaluation
A thorough functional assessment should be performed before treatment begins so that rehabilitation can be targeted and individualized. Because the hands are frequently affected by edema, Raynaud phenomenon, sclerodactyly, and reduced joint mobility, assessment should pay particular attention to upper-extremity function. Common limitations include fatigue, pain, impaired hand function, and reduced mobility²⁵.
Specific assessment tools include:
Health Assessment Questionnaire-Disability Index (HAQ-DI) – measures functional limitations in activities of daily living.
Scleroderma Health Assessment Questionnaire (SHAQ) – a modified questionnaire that includes problems related to Raynaud phenomenon and digital ulcers²⁶.
Hand Mobility in Scleroderma (HAMIS) – a validated test battery assessing hand mobility through nine functional tasks²⁷.
Exercise and Orthoses
Regular physical activity is an important non-pharmacological intervention and may help maintain function, physical capacity, and quality of life in systemic sclerosis. Exercise may also influence inflammatory and vascular pathways, although the clinical effects vary between individuals²⁸.
Hand exercises should particularly address:
MCP joint flexion (metacarpophalangeal joints)
PIP joint extension (proximal interphalangeal joints)
Thumb flexion and abduction
Daily hand-stretching exercises may improve mobility and the ability to perform activities of daily living²⁹.
Orthoses and splints:
Dynamic splints should be used cautiously because external pressure and prolonged positioning may aggravate symptoms in people with severe Raynaud phenomenon or vascular compromise.
Static splints may be useful in selected cases, particularly for positioning and contracture management, but should be individually fitted and monitored for pressure and circulatory effects²⁹.
Examples of exercise interventions that may form part of rehabilitation include²⁸:
Hand exercises: Mobility and strengthening exercises for the fingers to help limit stiffness and contracture.
Orofacial exercises: Particularly relevant for microstomia to maintain or improve mouth opening, eating, oral hygiene, and speech-related function.
Aerobic exercise: Low- to moderate-intensity activity such as walking or cycling, adjusted to cardiopulmonary status, symptoms, and fatigue.
Strength training: With particular emphasis on proximal muscle groups and functional strength needed for activities of daily living.
Range-of-Motion (ROM) Exercise: Used to maintain joint mobility and reduce the risk of contracture.
Kinesiotherapy: Functional movement training with individually guided progression.
Aquatic Exercise: Exercise in a warm-water pool may reduce perceived stiffness and facilitate movement in selected patients, provided vascular and cardiopulmonary precautions are considered.
Recreational Activity: Meaningful activities such as gardening, adapted sports, or other recreational exercise can support physical activity and social participation.
Physical Modalities and Occupational Therapy in CREST Syndrome
Various physical modalities and occupational-therapy interventions may contribute to improving function, reducing symptoms, and supporting quality of life in patients with limited systemic sclerosis. These interventions should be individualized and integrated into a broader rehabilitation plan.
Pulsed Dye Laser (PDL) for Telangiectasia
PDL is an established laser treatment based on selective photothermolysis, targeting superficial blood vessels while limiting injury to surrounding tissue. It can be used for telangiectasias on the face, hands, and other visible areas. Studies have reported substantial reduction in telangiectasia after one or more treatments, although response varies between patients³⁰.
Heat Therapy With Paraffin Wax
Local heat, including paraffin-wax treatment, has been used to improve hand comfort and mobility in systemic sclerosis. The thermal effect may temporarily increase tissue extensibility and facilitate hand exercise. Earlier studies reported immediate improvements in joint mobility, while later studies have produced mixed results regarding added benefit beyond exercise alone³¹,³².
Manual Lymphatic Drainage (MLD)
MLD is a specialized manual technique intended to support lymphatic drainage and reduce edema. Lymphatic abnormalities, microvascular changes, and inflammation may contribute to swelling of the hands and upper extremities in systemic sclerosis³³. Hand edema can reduce grip strength, slow movement, increase pain, and interfere with daily activities. Small studies and case reports suggest that MLD may improve swelling and some patient-reported outcomes when used as part of a broader rehabilitation program, but the evidence base remains limited³³.
Occupational Therapy and Adaptation of Daily Activities
Occupational therapy has an important role in supporting independence and participation in daily life. Patients with CREST syndrome may benefit from ergonomic strategies, energy conservation, joint protection, and compensatory techniques. Assessment of the home and workplace can identify barriers and guide appropriate adaptations³⁴. Assistive devices may reduce load on small joints and simplify tasks such as dressing, personal hygiene, food preparation, and device use. Examples include reachers, ergonomic kitchen tools, long-handled shoehorns, and adapted cutlery.
People with scleroderma who are working may also benefit from ergonomic assessment of their workstation, including adjustments to chair position, desk height, mouse, and keyboard. Such adaptations may help maintain work participation and reduce load-related symptom aggravation³⁴.
Kilder:
Meyer O. CREST syndrome. Ann Med Interne (Paris) [Internet]. 2002;153(3):183–8.
Le C, Bedocs PM. Calcinosis Cutis. StatPearls Publishing; 2023.
Nelson FRT, Blauvelt CT. The Hand and wrist. In: Nelson FRT, Blauvelt CT, editors. A Manual of Orthopaedic Terminology. Elsevier; 2015. p. 307–41.
Telangiectasia (Spider Veins) [Internet]. Pennmedicine.org. [cited 2023 Sep 8]. : https://www.pennmedicine.org/for-patients-and-visitors/patient-information/conditions-treated-a-to-z/telangiectasia-spider-veins
Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol [Internet]. 2019;11:257–73.
Wangkaew S, Euathrongchit J, Wattanawittawas P, Kasitanon N, Louthrenoo W. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study. Mod Rheumatol [Internet]. 2016;26(4):588–93.
Lescoat A, Varga J, Matucci-Cerinic M, Khanna D. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opin Investig Drugs [Internet]. 2021;30(6):635–52.
De Martinis M, Ciccarelli F, Sirufo MM, Ginaldi L. An overview of environmental risk factors in systemic sclerosis. Expert Rev Clin Immunol [Internet]. 2016;12(4):465–78.
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis and rheumatism [Internet]. 2013 [cited 2023 Sep 8];65(11).
Hsu V, Varga J, Schlesinger N. Calcinosis in scleroderma made crystal clear. Curr Opin Rheumatol [Internet]. 2019;31(6):589–94.
Chang SH, Jun JB, Lee YJ, Kang TY, Moon KW, Ju JH, et al. A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis. Rheumatology (Oxford) [Internet]. 2021;60(12):5814–9.
1. Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, Matucci-Cerinic M. Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol [Internet]. 2020;16(4):208–21.
Li B, Yan J, Pu J, Tang J, Xu S, Wang X. Esophageal dysfunction in systemic sclerosis: An update. Rheumatol Ther [Internet]. 2021;8(4):1535–49.
Adigun R, Goyal A, Hariz A. Systemic Sclerosis. StatPearls Publishing; 2022.
Foti R, De Pasquale R, Dal Bosco Y, Visalli E, Amato G, Gangemi P, et al. Clinical and histopathological features of Scleroderma-like disorders: An update. Medicina (Kaunas) [Internet]. 2021;57(11):1275.
Halachmi S, Gabari O, Cohen S, Koren R, Amitai DB, Lapidoth M. Telangiectasis in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment. Lasers Med Sci [Internet]. 2014;29(1):137–40.
Joslin N. Early identification key to scleroderma treatment. Nurse Pract [Internet]. 2004;29(7):24–39; quiz 40–1.
Gelber AC, Wigley FM. Disease severity as a predictor of outcome in scleroderma. Lancet [Internet]. 2002;359(9303):277–9.
Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, Matucci-Cerinic M. Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol [Internet]. 2020;16(4):208–21.
Herrick AL, Philobos M. Pharmacological management of digital ulcers in systemic sclerosis - what is new? Expert Opin Pharmacother [Internet]. 2023;24(10):1159–70.
Kempanna Y. P28 Recalcitrant exuberant digital calcinosis cutis in a patient of CREST syndrome - A case report. Rheumatol Adv Pract [Internet]. 2022;6(Supplement_1).
Nassar M, Ghernautan V, Nso N, Nyabera A, Castillo FC, Tu W, et al. Gastrointestinal involvement in systemic sclerosis: An updated review. Medicine (Baltimore) [Internet]. 2022;101(45):e31780.
Kawakibi AR, Khouri AN, Cederna PS, Strong AL. Novel indications for autologous fat grafting in reconstruction: scleroderma. Plast Aesthet Res [Internet]. 2023;10(0):48.
Cohen A, Morrow H, Cleary G. Physiotherapy and rheumatological disorders. Paediatr Child Health (Oxford) [Internet]. 2014;24(2):83–8.
Willems LM, Vriezekolk JE, Schouffoer AA, Poole JL, Stamm TA, Boström C, et al. Effectiveness of nonpharmacologic interventions in systemic sclerosis: A systematic review: Nonpharmacologic care in SSc. Arthritis Care Res (Hoboken) [Internet]. 2015;67(10):1426–39.
Johnson SR, Hawker GA, Davis AM. The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: An evaluation of their measurement properties. Arthritis Rheum [Internet]. 2005;53(2):256–62.
Sandqvist G, Eklund M. Hand mobility in scleroderma (HAMIS) test: The reliability of a novel hand function test. Arthritis Rheum [Internet]. 2000;13(6):369–74.
Frade S, Cameron M, Espinosa-Cuervo G, Suarez-Almazor ME, Lopez-Olivo MA. Exercise and physical therapy for systemic sclerosis. Cochrane Libr [Internet]. 2022;2022(3).
Krysia Dziedzic, Hammond A. Rheumatology : evidence-based practice for physiotherapists and occupational therapists. Edinburgh: Churchill Livingstone; 2010.
Halachmi S, Gabari O, Cohen S, Koren R, Amitai DB, Lapidoth M. Telangiectasis in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment. Lasers Med Sci [Internet]. 2014;29(1):137–40.
Askew LJ, Backett VL, An K-N, Chao EYS. Objective evaluation of hand function in scleroderman patients to assess effectiveness of physical therapy. Rheumatology (Oxford) [Internet]. 1983;22(4):224–32.
Kristensen LQ, Oestergaard LG, Bovbjerg K, Rolving N, Søndergaard K. Use of paraffin instead of lukewarm water prior to hand exercises had no additional effect on hand mobility in patients with systemic sclerosis: A randomized clinical trial. Hand Ther [Internet]. 2019;24(1):13–21.
Yılmaz A, Çalık BB, Kabul EG, Tasçı M, Çobankara V. Efficacy of manual lymph drainage in systemic sclerosis: A case report. Ann Clin Anal Med [Internet]. 2021;12(Suppl_03):3): S354.
Barange J. Case Study of Physiotherapy Treatment of a Patient with the Diagnosis Scleroderma.
